Sight Sciences, Inc. (SGHT)

Several significant events impacted Sight Sciences' stock in the past six months. In Q3 2025, the company reported a slight revenue decrease but an increase in Surgical Glaucoma revenue, along with reduced operating expenses. In Q4 2025, Sight Sciences reported a revenue increase and a high gross margin, initiating full-year 2026 revenue guidance. A U.S. District Court issued an order preserving a jury's verdict that Alcon willfully infringed three of Sight Sciences' patents, awarding monetary damages and an ongoing royalty. In Q1 2026, the company reported a revenue increase driven by growth in both Interventional Glaucoma and Interventional Dry Eye, with a strong gross margin and reduced cash usage, raising its full-year 2026 revenue guidance. SGHT stock has traded between $2.81 and $9.24 over the past 52 weeks, with a stock price of $4.30 as of May 6, 2026.

Based on the available information, there is no explicit mention or indication of significant demand seasonality for Sight Sciences, Inc.'s products and services.

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing surgical and non-surgical technologies for the treatment of prevalent eye diseases, operating within the Healthcare sector. The company's business model centers on the surgical treatment of glaucoma and the in-office treatment of dry eye disease. Its major products include the OMNI Surgical System, a minimally invasive glaucoma surgery device; the SION Surgical Instrument, a bladeless device used in ophthalmic surgical procedures; and the TearCare System, a wearable eyelid technology for localized heat therapy in adult patients with evaporative dry eye disease.

Sight Sciences primarily operates and generates nearly all of its revenue within the United States, targeting eye care professionals in hospitals, ambulatory surgery centers, and private practices. The OMNI Surgical System is also accessible in 11 countries worldwide.

Sight Sciences emphasizes its mission to develop transformative, interventional technologies that elevate the standards of eye care, highlighting its commitment to innovation, patent-protected technology, and top-tier clinical evidence. The company released its Sustainability Report in April 2026, providing data on its environmental, social, and governance initiatives. The ongoing patent litigation with Alcon is a significant financial and legal event, and the company's focus on safeguarding its intellectual property underscores its commitment to its innovations.

Sight Sciences, Inc. has a diverse ownership structure, with institutional shareholders holding 36.19% and insiders holding 57.51% of the company. Major institutional owners include Long Focus Capital Management, Llc, BlackRock, Inc., and Vanguard Group Inc. Key individual and insider owners include Paul Badawi (CEO and Co-Founder), Staffan Encrantz, and KCK Group.